Brian Carlin, MD, FCCP, Allegheny General Hospital, discusses the challenges in reducing 30-day readmission rates, specifically as they apply to congestive heart failure, pneumonia, and COPD. The biggest challenge of all is setting up a coordinated team care effort, says Dr Carlin.
Brian Carlin, MD, FCCP, Allegheny General Hospital, discusses the challenges in reducing 30-day readmission rates, specifically as they apply to congestive heart failure, pneumonia, and COPD. The biggest challenge of all is setting up a coordinated team care effort, says Dr Carlin.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
Rurality, Long Travel Times Limit Access to Tobacco Treatment for Patients With COPD Who Smoke
August 30th 2025Patients with chronic obstructive pulmonary disease (COPD) who smoke were less likely to receive tobacco dependence treatment (TDT) if they lived in rural areas or had longer travel times to care, highlighting persistent geographic disparities in access.
Read More